Rescue of pulmonary hypertension with an oral sulfonamide antibiotic sulfisoxazole by endothelin receptor antagonistic actions

Hypertension Research

Volumn 31, Issue 9, 2008, Pages 1781-1790

  Uchino, Tomoko ^a   Sanyal, Shamarendra N ^a   Yamabe, Motoko ^a   Kaku, Toshihiko ^a   Takebayashi, Satoshi ^a   Shimaoka, Toru ^a   Shimada, Tatsuo ^a   Noguchi, Takayuki ^a   Ono, Katsushige ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Atrial natriuremic peptide; Endothelin; Heart rate variability; Pulmonary hypertension; Sulfisoxazole

Indexed keywords

ATRIAL NATRIURETIC FACTOR; MONOCROTALINE; SULFAFURAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; HEART MUSCLE CELL; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NERVE CONDUCTION; NONHUMAN; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SURVIVAL RATE;

EID: 55449102531     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1781     Document Type: Article

References (31)

1. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Opgenorth TJ, Wu-Wong JR, Shiosaki K: Endothelin-converting enzymes. FASEB J 1992; 6: 2653-2659.
3. Rubens C, Ewert R, Halank M, et al: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
4. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
5. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
6. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995; 79: 2122-2131.
7. Ichikawa K, Hidai C, Okuda C, et al: Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27: 1286-1291.
8. Wiedemann R, Ghofrani HA, Weissmann N, et al: Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. J Am Coll Cardiol 2001; 38: 1130-1136.
9. Chan MF, Okun I, Stavros FL, Hwang E, Wolff ME, Balaji VN: Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem Biophys Res Commun 1994; 201: 228-234.
10. Mandell GL, Petri WA Jr: Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections, in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds): Goodman & Gillman's the Pharmacological Basis of Therapeutics, 9th ed. New York, The McGraw-Hill Companies, 1996, pp 1057-1072.
11. Brown L, Miller J, Dagger A, Sernia C: Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol 1998; 31: 108-115.
12. Sanyal SN, Ono K: Derangement of autonomic nerve control in rat with right ventricular failure. Pathophysiology 2002; 8: 197-203.
13. Bellavere F, Balzani I, Masi GD, et al: Power spectral analysis of heart-rate variations improves assessment of diabetic cardiac autonomic neuropathy. Diabetes 1992; 41: 633-640.
14. Radin MJ, Jenkins JE, McCune SA, Jurin RR, Hamlin RL: Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats. J Cardiovasc Pharmacol 1992; 19: 464-472.
15. Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ: Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220-222.
16. Rich S, McLaughlin VV: Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108: 2184-2190.
17. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001; 103: 314-318.
18. Miyauchi T, Yorikane R, Sakai S, et al: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993; 73: 887-897.
19. Galie N, Hinderliter AL, Torbicki A, et al: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386.
20. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ: Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 62S-67S.
21. A receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 2004; 496: 129-139.
22. Wada A, Tsutamoto T, Fukai D, et al: Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30: 1385-1392.
23. A/B receptor antagonist in heart failure. Cardiovasc Res 1998; 39: 617-624.
24. Yamauchi-Kohno R, Miyauchi T, Hoshino T, et al: Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999; 99: 2171-2176.
25. Torre-Amione G, Young JB, Colucci WS, et al: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42: 140-147.
26. + current in human ventricular cardiomyocytes. Cardiovasc Res 2006; 69: 116-127.
27. Kaab S, Dixon J, Duc J, et al: Molecular basis of transient outward potassium current downregulation in human heart failure. Circulation 1998; 98: 1383-1393.
28. Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Fauchier JP: Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 2004; 6: 181-185.
29. Klinger JR, Warburton RR, Pietras LA, Smithies O, Swift R, Hill NS: Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am J Physiol 1999; 276: L868-L874.
30. Nagaya N, Nishikimi T, Okano Y, et al: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
31. Berman S, Byrns PJ, Bondy J, Smith PJ, Lezotte D: Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population. Pediatrics 1997; 100: 585-592.